Fundraising FoxEvogen, Inc.
Lower Gwynedd, US
Find your way into Evogen, Inc.
Sign up to see every warm intro you have to Evogen, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Evogen, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Evogen develops proteomics and genomics diagnostic technologies for neurology precision medicine, including a biomarker-based blood test (EvoScore) for epilepsy and seizure diagnosis. The company also offers HyBeacons PCR reagent technology for pathogen detection and the SpinCon air sampler for collecting airborne biothreats, serving healthcare providers and biodefense applications.
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$852.4K disclosed across 1 round · 2014
▶$852.4KraisedFeb 2014 · 8 investors · BiotechnologyRule 506(b)
- Nathan LedeboerDirector
- Hans KastensmithExecutive Officer, Director, Promoter
- Richard St. ClairExecutive Officer
- Jonathan LeitersdorfDirector
- Robert DondesExecutive Officer
- Sean ReinekeDirector
- Offering amount
- $1.6M
- Amount sold
- $852.4K
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $617.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.5K |
| U.S. ArmyArmy | Phase II | 2012 | $720K |
| U.S. ArmyArmy | Phase I | 2011 | $69.5K |
| Department of Homeland Security | Phase I | 2006 | $98.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Evogen, Inc. do?
- Evogen develops proteomics and genomics diagnostic technologies for neurology precision medicine, including a biomarker-based blood test (EvoScore) for epilepsy and seizure diagnosis. The company also offers HyBeacons PCR reagent technology for pathogen detection and the SpinCon air sampler for collecting airborne biothreats, serving healthcare providers and biodefense applications.
- Who founded Evogen, Inc.?
- Evogen, Inc. was founded by Hans Kastensmith.
- How much funding has Evogen, Inc. raised?
- Evogen, Inc. has disclosed $852.4K raised across 1 round.
- Where is Evogen, Inc. headquartered?
- Evogen, Inc. is headquartered in Lower Gwynedd, US.